Angelini Ventures
Headquarter
Copenhagen, Denmark
Milestones
Founded: 2020
Invested: 2024
Founders / CEO
Janine Erler
Vertical
Biotech
Board Participation
Thomas Thestrup, Board Member
Developer of ribonucleic acid therapies intended to treat neurological disorders. The company provides anti-miRNA treatment for transformative disease modification for neurological conditions, enabling healthcare professionals to treat patients suffering from epilepsy.
Related news:
Advancing neuroscience: Angelini Ventures invests in Neumirna’s innovative RNA therapeutics